[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity
Andrew John Hugh MacIntyre Sims, listed as Chief Financial Officer and Director of Plus Therapeutics, Inc. (PSTV), filed a Form 4 disclosing insider changes effective 10/01/2025. The filing reports the vesting of 38,323 Restricted Stock Units (RSUs) that are each a contingent right to one share, recorded with a transaction code M and a reported price of $0. After the reported transaction the filing shows 48,138 shares of Common Stock beneficially owned directly and 421,555 derivative securities (RSUs) reported as beneficially owned following the transaction. The filing states these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025.
Andrew John Hugh MacIntyre Sims, registrato come Direttore Finanziario e Amministratore di Plus Therapeutics, Inc. (PSTV), ha presentato un Modulo 4 divulguando cambiamenti interni efficaci il 01/10/2025. Il deposito riporta l'acquisizione di 38.323 RSU (Restricted Stock Units) che ciascuna costituisce un diritto contingentato a una quota azionaria, registrate con codice di transazione M e prezzo riportato di $0. Dopo la transazione riportata, il deposito mostra 48.138 azioni ordinarie possedute direttamente e 421.555 strumenti derivati (RSU) riportati come posseduti beneficiariamente a seguito della transazione. Il deposito afferma che tali RSU maturano in dodici rate trimestrali sostanzialmente uguali a partire dal 01/10/2025.
Andrew John Hugh MacIntyre Sims, registrado como Director Financiero y Director de Plus Therapeutics, Inc. (PSTV), presentó un Formulario 4 divulgando cambios internos con efecto a partir del 01/10/2025. El registro reporta la adquisición de 38.323 Restricted Stock Units (RSU), cada una de las cuales es un derecho contingente a una acción, registrada con un código de transacción M y un precio informado de $0. Después de la transacción reportada, el registro muestra 48.138 acciones comunes poseídas directamente y 421.555 valores derivados (RSU) reportados como poseídos beneficiosamente tras la transacción. El registro indica que estas RSU vencen en doce cuotas trimestrales sustancialmente iguales, a partir del 01/10/2025.
Andrew John Hugh MacIntyre Sims는 Plus Therapeutics, Inc. (PSTV)의 최고 재무 책임자(CFO) 및 이사로 등재되어 있으며, 2025년 10월 1일에 효력이 있는 내부자 변경 사항을 공개하는 Form 4를 제출했습니다. 보고서는 각 1주당 주권권리인 38,323개의 Restricted Stock Units(RSUs)이 포괄되며 거래 코드 M와 보고된 가격 $0으로 기록되었음을 보고합니다. 보고된 거래 후, 이 서류는 직접 소유한 일반 주식 48,138주와 거래 후 유익하게 소유된 파생 증권(RSUs) 421,555주를 표시합니다. 이 RSU는 매년 12회에 걸쳐 거의 동일하게 분할 vesting되며 시작일은 2025년 10월 1일입니다.
Andrew John Hugh MacIntyre Sims, enregistré comme Directeur financier et Directeur de Plus Therapeutics, Inc. (PSTV), a déposé un Formulaire 4 divulguant des changements internes effectifs à partir du 01/10/2025. Le dépôt indique la consolidation de 38 323 Restricted Stock Units (RSU), chacune constituant un droit conditionnel sur une action, enregistrées avec un code de transaction M et un prix déclaré de $0. Après la transaction signalée, le formulaire montre 48 138 actions ordinaires détenues directement et 421 555 titres dérivés (RSU) déclarés comme détenus de manière bénéficiaire à la suite de la transaction. Le formulaire indique que ces RSU vestiront en douze versements trimestriels sensiblement égaux à partir du 01/10/2025.
Andrew John Hugh MacIntyre Sims, geführt als Finanzvorstand und Direktor von Plus Therapeutics, Inc. (PSTV), hat ein Form 4 eingereicht, das Insider-Änderungen mit Wirkung zum 01.10.2025 offenlegt. Die Einreichung meldet die Vergabe von 38.323 Restricted Stock Units (RSUs), von denen jede ein bedingtes Recht auf eine Aktie darstellt, registriert mit dem Transaktionscode M und einem angegebenen Preis von $0. Nach der gemeldeten Transaktion zeigt die Einreichung 48.138 Directly Owned Common Stock und 421.555Derivative Securities (RSUs) als vorteilhaft gehalten nach der Transaktion. Die Einreichung besagt, dass diese RSUs in zwölf nahezu gleichen vierteljährlichen Teilzahlungen ab dem 01.10.2025 vesten.
أندرو جون هيو ماكنتير سِمز، المدرج كـ مدير مالي تنفيذي و مدير لشركة Plus Therapeutics, Inc. (PSTV)، قد قدّم نموذج 4 يكشف عن تغييرات داخلية سارية المفعول اعتباراً من 01/10/2025. يفيد التسجيل بوجود منح لـ 38,323 وحدات أسهم مقيدة RSU، كل منها حق مشروط في سهم واحد، مسجّلة برمز المعاملة M وبسعر مُبلّغ عنه $0. بعد المعاملة المذكورة يظهر التسجيل 48,138 سهمًا من الأسهم العادية مملوكة مباشرة و421,555 ورقة مالية مشتقة (RSUs) مُعلَن عنها كمالكة مستفيدة عقب المعاملة. تنص الوثيقة أن هذه RSU ستتحصل (vest) على افتراد اثني عشر دفعة ربع سنوية متساوية تقريبا ابتداءً من 01/10/2025.
Andrew John Hugh MacIntyre Sims，被列为Plus Therapeutics, Inc.（PSTV）的首席财务官和 董事，提交了生效日期为2025-10-01的Form 4，披露内部人变动。该申报报告了
- 38,323 RSUs vested to the reporting person, increasing immediate share ownership
- Vesting schedule disclosed: RSUs vest in 12 substantially equal quarterly installments beginning 10/01/2025, showing a predictable compensation timeline
- None.
Insights
Insider vested 38,323 RSUs; ongoing multi-quarter vesting schedule disclosed.
The Form 4 shows an insider vesting event recorded under transaction code M on 10/01/2025, representing the conversion of 38,323 RSUs into common shares at a reported price of $0. The filing also reports remaining derivative holdings of 421,555 RSUs and direct ownership of 48,138 shares after the transaction.
This matters because the filing documents a scheduled compensation vesting rather than an open-market purchase or sale; the disclosed RSU tranche is part of a planned, time-based vesting that will occur in twelve substantially equal quarterly installments beginning 10/01/2025.
Andrew John Hugh MacIntyre Sims, registrato come Direttore Finanziario e Amministratore di Plus Therapeutics, Inc. (PSTV), ha presentato un Modulo 4 divulguando cambiamenti interni efficaci il 01/10/2025. Il deposito riporta l'acquisizione di 38.323 RSU (Restricted Stock Units) che ciascuna costituisce un diritto contingentato a una quota azionaria, registrate con codice di transazione M e prezzo riportato di $0. Dopo la transazione riportata, il deposito mostra 48.138 azioni ordinarie possedute direttamente e 421.555 strumenti derivati (RSU) riportati come posseduti beneficiariamente a seguito della transazione. Il deposito afferma che tali RSU maturano in dodici rate trimestrali sostanzialmente uguali a partire dal 01/10/2025.
Andrew John Hugh MacIntyre Sims, registrado como Director Financiero y Director de Plus Therapeutics, Inc. (PSTV), presentó un Formulario 4 divulgando cambios internos con efecto a partir del 01/10/2025. El registro reporta la adquisición de 38.323 Restricted Stock Units (RSU), cada una de las cuales es un derecho contingente a una acción, registrada con un código de transacción M y un precio informado de $0. Después de la transacción reportada, el registro muestra 48.138 acciones comunes poseídas directamente y 421.555 valores derivados (RSU) reportados como poseídos beneficiosamente tras la transacción. El registro indica que estas RSU vencen en doce cuotas trimestrales sustancialmente iguales, a partir del 01/10/2025.
Andrew John Hugh MacIntyre Sims는 Plus Therapeutics, Inc. (PSTV)의 최고 재무 책임자(CFO) 및 이사로 등재되어 있으며, 2025년 10월 1일에 효력이 있는 내부자 변경 사항을 공개하는 Form 4를 제출했습니다. 보고서는 각 1주당 주권권리인 38,323개의 Restricted Stock Units(RSUs)이 포괄되며 거래 코드 M와 보고된 가격 $0으로 기록되었음을 보고합니다. 보고된 거래 후, 이 서류는 직접 소유한 일반 주식 48,138주와 거래 후 유익하게 소유된 파생 증권(RSUs) 421,555주를 표시합니다. 이 RSU는 매년 12회에 걸쳐 거의 동일하게 분할 vesting되며 시작일은 2025년 10월 1일입니다.
Andrew John Hugh MacIntyre Sims, enregistré comme Directeur financier et Directeur de Plus Therapeutics, Inc. (PSTV), a déposé un Formulaire 4 divulguant des changements internes effectifs à partir du 01/10/2025. Le dépôt indique la consolidation de 38 323 Restricted Stock Units (RSU), chacune constituant un droit conditionnel sur une action, enregistrées avec un code de transaction M et un prix déclaré de $0. Après la transaction signalée, le formulaire montre 48 138 actions ordinaires détenues directement et 421 555 titres dérivés (RSU) déclarés comme détenus de manière bénéficiaire à la suite de la transaction. Le formulaire indique que ces RSU vestiront en douze versements trimestriels sensiblement égaux à partir du 01/10/2025.
Andrew John Hugh MacIntyre Sims, geführt als Finanzvorstand und Direktor von Plus Therapeutics, Inc. (PSTV), hat ein Form 4 eingereicht, das Insider-Änderungen mit Wirkung zum 01.10.2025 offenlegt. Die Einreichung meldet die Vergabe von 38.323 Restricted Stock Units (RSUs), von denen jede ein bedingtes Recht auf eine Aktie darstellt, registriert mit dem Transaktionscode M und einem angegebenen Preis von $0. Nach der gemeldeten Transaktion zeigt die Einreichung 48.138 Directly Owned Common Stock und 421.555Derivative Securities (RSUs) als vorteilhaft gehalten nach der Transaktion. Die Einreichung besagt, dass diese RSUs in zwölf nahezu gleichen vierteljährlichen Teilzahlungen ab dem 01.10.2025 vesten.
FAQ
What did Plus Therapeutics (PSTV) disclose in this Form 4?
How are the RSUs described in the filing structured?
What transaction code was used and what does it indicate?
What amount of securities does the reporting person own after the transaction?
When was the Form 4 signed?
